Physician profile
Len N Getz
NPI 1831172444
$25,228.03
in general payments reported to CMS, 2019-2025
27 companies · $984 in 2025
The $984 reported for 2025 was more than what 87% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $23K · 2022: $544 · 2023: $350 · 2024: $809 · 2025: $984.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,142.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,142.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $22,762.81 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $460.14 | 2021-2025 | Trintellix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $235.28 | 2025 | Caplyta |
| Alkermes, INC. | $235.24 | 2023-2025 | Lybalvi, Aristada |
| Kowa Pharmaceuticals America, INC. | $211.59 | 2021-2025 | Livalo, Zoryve, Seglentis |
| Astrazeneca Pharmaceuticals LP | $177.70 | 2022-2024 | Farxiga |
| Vanda Pharmaceuticals INC. | $175.29 | 2024 | Fanapt, Hetlioz |
| Corium, LLC | $158.41 | 2022-2025 | Azstarys |
| Lilly USA, LLC | $147.12 | 2021-2024 | Zepbound, Jardiance |
| Novo Nordisk INC | $130.06 | 2021-2025 | Rybelsus, Ozempic |
| Boston Scientific Corporation | $75.51 | 2024 | Wavewriter Alpha Prime 16 |
| Otsuka America Pharmaceutical, INC. | $65.75 | 2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $55.89 | 2023-2025 | Spravato |
| Evoke Pharma, INC. | $52.98 | 2024-2025 | |
| Supernus Pharmaceuticals, INC. | $40.96 | 2022-2024 | Qelbree, Qelbree |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $36.55 | 2025 | Auvelity |
| Ironshore Pharmaceuticals INC. | $31.67 | 2022 | |
| Astellas Pharma US INC | $26.24 | 2024 | Veozah |
| Azurity Pharmaceuticals, INC. | $20.39 | 2023 | Horizant |
| Amgen INC. | $19.58 | 2022 | |
| Hikma Pharmaceuticals USA | $19.41 | 2025 | Ryaltris |
| Merck Sharp & Dohme LLC | $16.18 | 2022 | |
| Pfizer INC. | $15.53 | 2024 | |
| Biogen, INC. | $15.30 | 2025 | Zurzuvae |
| Shield Therapeutics INC | $14.63 | 2023 | Accrufer |
| Genentech USA, INC. | $14.22 | 2021 | |
| Idorsia Pharmaceuticals US INC | $13.60 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Len Getz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.